October 11, 2017October 11, 2017

BioXcel Presents Data on Potential Therapy at Prostate Cancer Foundation Retreat in D.C.

News

BioXcel Therapeutics’ immuno-oncology candidate BXCL701 was shown to enhance the anti-tumor effects of immune checkpoint inhibitors in prostate models, according to an Oct. 5 poster session at the 24th Annual ... Read more

April 21, 2017April 21, 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

News

Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company. Dr. Luca Rastelli, BioXCel’s vice-president for oncology research ... Read more